XNASCOGT
Market cap866mUSD
Jan 13, Last price
7.57USD
1D
-3.33%
1Q
-30.31%
IPO
-27.07%
Name
Cogent Biosciences Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
66.51%
Rev. gr., 5y
49.73%
Revenues
0k
Net income
-192m
L+45.06%
CFO
-154m
L+29.49%
Earnings
Feb 24, 2025
Profile
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 211,718 | 153,717 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (211,718) | (153,717) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (7,598) | ||||||||
Tax Rate | |||||||||
NOPAT | (211,718) | (146,119) | |||||||
Net income | (192,410) 45.06% | (132,643) 84.72% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 161,819 | 163,558 | |||||||
BB yield | -34.55% | -24.09% | |||||||
| Debt | |||||||||
Debt current | 2,772 | 1,423 | |||||||
Long-term debt | 36,320 | 37,875 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (234,078) | (219,978) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (153,624) | (118,638) | |||||||
CAPEX | (2,796) | (6,863) | |||||||
Cash from investing activities | (97,824) | (124,718) | |||||||
Cash from financing activities | 163,536 | 163,558 | |||||||
FCF | (210,961) | (172,741) | |||||||
| Balance | |||||||||
Cash | 265,710 | 259,276 | |||||||
Long term investments | 7,460 | ||||||||
Excess cash | 273,170 | 259,276 | |||||||
Stockholders' equity | (543,257) | (345,418) | |||||||
Invested Capital | 821,298 | 620,802 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 79,658 | 58,740 | |||||||
Price | 5.88 -49.13% | 11.56 34.73% | |||||||
Market cap | 468,389 -31.02% | 679,031 104.34% | |||||||
EV | 294,346 | 524,883 | |||||||
EBITDA | (208,130) | (147,839) | |||||||
EV/EBITDA | |||||||||
Interest | 3,989 | ||||||||
Interest/NOPBT | |||||||||